ProQR, Galapagos in oligonucleotide deal for fibrosis

ProQR Therapeutics N.V. (NASDAQ:PRQR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) partnered to discover Axiomer Editing Oligonucleotides (EONs) against Galapagos' fibrosis targets using ProQR's Axiomer RNA technology. Deal terms were not disclosed.

ProQR's EONs mediate single nucleotide changes to RNA using molecular machinery inside human cells by recruiting an endogenously expressed RNA editing system called Adenosine Deaminase Acting on RNA (ADAR). ...